Literature DB >> 24596063

Loss of HSulf-1 expression enhances tumorigenicity by inhibiting Bim expression in ovarian cancer.

Xiaoping He1, Ashwani Khurana, Debarshi Roy, Scott Kaufmann, Viji Shridhar.   

Abstract

The expression of human Sulfatase1 (HSulf-1) is downregulated in the majority of primary ovarian cancer tumors, but the functional consequence of this downregulation remains unclear. Using two different shRNAs (Sh1 and Sh2), HSulf-1 expression was stably downregulated in ovarian cancer OV202 cells. We found that HSulf-1-deficient OV202 Sh1 and Sh2 cells formed colonies in soft agar. In contrast, nontargeting control (NTC) shRNA-transduced OV202 cells did not form any colonies. Moreover, subcutaneous injection of OV202 HSulf-1-deficient cells resulted in tumor formation in nude mice, whereas OV202 NTC cells did not. Also, ectopic expression of HSulf-1 in ovarian cancer SKOV3 cells significantly suppressed tumor growth in nude mice. Here, we show that HSulf-1-deficient OV202 cells have markedly decreased expression of proapoptotic Bim protein, which can be rescued by restoring HSulf-1 expression in OV202 Sh1 cells. Enhanced expression of HSulf-1 in HSulf-1-deficient SKOV3 cells resulted in increased Bim expression. Decreased Bim levels after loss of HSulf-1 were due to increased p-ERK, because inhibition of ERK activity with PD98059 resulted in increased Bim expression. However, treatment with a PI3 kinase/AKT inhibitor, LY294002, failed to show any change in Bim protein level. Importantly, rescuing Bim expression in HSulf-1 knockdown cells significantly retarded tumor growth in nude mice. Collectively, these results suggest that loss of HSulf-1 expression promotes tumorigenicity in ovarian cancer through regulating Bim expression.
© 2014 UICC.

Entities:  

Keywords:  Bim; HSulf-1; ovarian cancer; tumorigenicity

Mesh:

Substances:

Year:  2014        PMID: 24596063      PMCID: PMC4346160          DOI: 10.1002/ijc.28818

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  23 in total

Review 1.  Apoptosis: controlled demolition at the cellular level.

Authors:  Rebecca C Taylor; Sean P Cullen; Seamus J Martin
Journal:  Nat Rev Mol Cell Biol       Date:  2008-03       Impact factor: 94.444

2.  HSulf-1 inhibits angiogenesis and tumorigenesis in vivo.

Authors:  Keishi Narita; Julie Staub; Jeremy Chien; Kristy Meyer; Maret Bauer; Andreas Friedl; Sundaram Ramakrishnan; Viji Shridhar
Journal:  Cancer Res       Date:  2006-06-15       Impact factor: 12.701

3.  Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance.

Authors:  J Staub; J Chien; Y Pan; X Qian; K Narita; G Aletti; M Scheerer; L R Roberts; J Molina; V Shridhar
Journal:  Oncogene       Date:  2007-02-19       Impact factor: 9.867

4.  Loss of HSulf-1 expression enhances autocrine signaling mediated by amphiregulin in breast cancer.

Authors:  Keishi Narita; Jeremy Chien; Sally A Mullany; Julie Staub; Xiang Qian; Wilma L Lingle; Viji Shridhar
Journal:  J Biol Chem       Date:  2007-03-15       Impact factor: 5.157

Review 5.  Bcl-2-regulated apoptosis: mechanism and therapeutic potential.

Authors:  Jerry M Adams; Suzanne Cory
Journal:  Curr Opin Immunol       Date:  2007-07-12       Impact factor: 7.486

6.  Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes.

Authors:  Changchun Xiao; Lakshmi Srinivasan; Dinis Pedro Calado; Heide Christine Patterson; Baochun Zhang; Jing Wang; Joel M Henderson; Jeffrey L Kutok; Klaus Rajewsky
Journal:  Nat Immunol       Date:  2008-03-09       Impact factor: 25.606

7.  Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion.

Authors:  Jing Deng; Takeshi Shimamura; Samanthi Perera; Nicole E Carlson; Dongpo Cai; Geoffrey I Shapiro; Kwok-Kin Wong; Anthony Letai
Journal:  Cancer Res       Date:  2007-12-15       Impact factor: 12.701

8.  The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.

Authors:  James Witham; Melanie R Valenti; Alexis K De-Haven-Brandon; Susanne Vidot; Suzanne A Eccles; Stan B Kaye; Alan Richardson
Journal:  Clin Cancer Res       Date:  2007-12-01       Impact factor: 12.531

9.  Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas.

Authors:  Cinta Mestre-Escorihuela; Fanny Rubio-Moscardo; Jose A Richter; Reiner Siebert; Joan Climent; Vicente Fresquet; Elena Beltran; Xabier Agirre; Isabel Marugan; Miguel Marín; Andreas Rosenwald; Kei-Ji Sugimoto; Luise M Wheat; E Loraine Karran; Juan F García; Lydia Sanchez; Felipe Prosper; Louis M Staudt; Daniel Pinkel; Martin J S Dyer; Jose A Martinez-Climent
Journal:  Blood       Date:  2006-09-07       Impact factor: 22.113

10.  Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters.

Authors:  Andrea Ventura; Amanda G Young; Monte M Winslow; Laura Lintault; Alex Meissner; Stefan J Erkeland; Jamie Newman; Roderick T Bronson; Denise Crowley; James R Stone; Rudolf Jaenisch; Phillip A Sharp; Tyler Jacks
Journal:  Cell       Date:  2008-03-07       Impact factor: 41.582

View more
  9 in total

1.  Integration and bioinformatics analysis of DNA-methylated genes associated with drug resistance in ovarian cancer.

Authors:  Bingbing Yan; Fuqiang Yin; Q I Wang; Wei Zhang; L I Li
Journal:  Oncol Lett       Date:  2016-05-18       Impact factor: 2.967

2.  Potential roles of Centipede Scolopendra extracts as a strategy against EGFR-dependent cancers.

Authors:  Weina Ma; Dongdong Zhang; Lei Zheng; Yingzhuan Zhan; Yanmin Zhang
Journal:  Am J Transl Res       Date:  2015-01-15       Impact factor: 4.060

3.  Down-regulation of ARID1A is sufficient to initiate neoplastic transformation along with epigenetic reprogramming in non-tumorigenic endometriotic cells.

Authors:  Ranjani Lakshminarasimhan; Claudia Andreu-Vieyra; Kate Lawrenson; Christopher E Duymich; Simon A Gayther; Gangning Liang; Peter A Jones
Journal:  Cancer Lett       Date:  2017-05-06       Impact factor: 8.679

4.  HSulf-1 deficiency dictates a metabolic reprograming of glycolysis and TCA cycle in ovarian cancer.

Authors:  Susmita Mondal; Debarshi Roy; Juliana Camacho-Pereira; Ashwani Khurana; Eduardo Chini; Lifeng Yang; Joelle Baddour; Katherine Stilles; Seth Padmabandu; Sam Leung; Steve Kalloger; Blake Gilks; Val Lowe; Thomas Dierks; Edward Hammond; Keith Dredge; Deepak Nagrath; Viji Shridhar
Journal:  Oncotarget       Date:  2015-10-20

5.  Loss of HSulf-1: The Missing Link between Autophagy and Lipid Droplets in Ovarian Cancer.

Authors:  Debarshi Roy; Susmita Mondal; Ashwani Khurana; Deok-Beom Jung; Robert Hoffmann; Xiaoping He; Eleftheria Kalogera; Thomas Dierks; Edward Hammond; Keith Dredge; Viji Shridhar
Journal:  Sci Rep       Date:  2017-02-07       Impact factor: 4.379

Review 6.  Cancer Cell Glycocalyx and Its Significance in Cancer Progression.

Authors:  Hongyan Kang; Qiuhong Wu; Anqiang Sun; Xiao Liu; Yubo Fan; Xiaoyan Deng
Journal:  Int J Mol Sci       Date:  2018-08-22       Impact factor: 5.923

Review 7.  The Role of Heparanase and Sulfatases in the Modification of Heparan Sulfate Proteoglycans within the Tumor Microenvironment and Opportunities for Novel Cancer Therapeutics.

Authors:  Edward Hammond; Ashwani Khurana; Viji Shridhar; Keith Dredge
Journal:  Front Oncol       Date:  2014-07-24       Impact factor: 6.244

8.  Loss of HSulf-1 promotes altered lipid metabolism in ovarian cancer.

Authors:  Debarshi Roy; Susmita Mondal; Chen Wang; Xiaoping He; Ashwani Khurana; Shailendra Giri; Robert Hoffmann; Deok-Beom Jung; Sung H Kim; Eduardo N Chini; Juliana Camacho Periera; Clifford D Folmes; Andrea Mariani; Sean C Dowdy; Jamie N Bakkum-Gamez; Shaun M Riska; Ann L Oberg; Edward D Karoly; Lauren N Bell; Jeremy Chien; Viji Shridhar
Journal:  Cancer Metab       Date:  2014-08-18

9.  SULF1 suppresses Wnt3A-driven growth of bone metastatic prostate cancer in perlecan-modified 3D cancer-stroma-macrophage triculture models.

Authors:  Fabio Henrique Brasil da Costa; Michael S Lewis; Anna Truong; Daniel D Carson; Mary C Farach-Carson
Journal:  PLoS One       Date:  2020-05-15       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.